Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that management will present a company overview at the 2023 Jefferies Healthcare Conference on Thursday, June 8, 2023, at 11:30 a.m. ET.
A live webcast of the presentation will be available here and in the news & press section of the company's website at www.mazetx.com. The webcast will be archived for 90 days following the presentation.
About Maze Therapeutics
Maze Therapeutics is a biopharmaceutical company that is harnessing the power of human genetics to transform the lives of patients, with a focus on genetically informed therapies for common diseases such as chronic kidney disease. Maze applies variant functionalization in tandem with advanced data science methods and a robust suite of research and development capabilities to advance a pipeline of novel precision medicines. Maze has developed the Maze Compass Platform TM, a proprietary, purpose-built platform to understand and integrate the critical step of variant functionalization into each stage of drug development. Utilizing the Maze Compass PlatformTM, Maze is building a broad portfolio of wholly owned and partnered programs. Maze is based in South San Francisco. For more information, please visit mazetx.com, or follow us on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230601005070/en/
Contacts
Jillian Connell, Maze Therapeutics
jconnell@mazetx.com
(650) 850-5080
Media:
Dan Budwick, 1AB
dan@1abmedia.com